慢性乙型肝炎主要抗病毒新药研发现状  

Research and development of major new antiviral drugs for chronic hepatitis B

作　　者：马亦林[1] Ma Yilin(Department of Infectious Diseases,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院感染病科,传染病重症诊治全国重点实验室,国家感染性疾病临床医学研究中心,杭州310003

出　　处：《中华临床感染病杂志》2024年第4期263-282,共20页Chinese Journal of Clinical Infectious Diseases

摘　　要：乙型病毒性肝炎已成为严重威胁人类健康的世界性疾病,也是我国当前流行最为广泛、危害性严重的传染病之一。据Polaris Observatory Collaborators公布数据显示,2022年我国HBV感染者达7 974万人。近两年来,随着科学技术的发展,新药物研发突飞猛进,越来越多的新型抗乙型肝炎治疗小分子药物及免疫调控抑制剂进入临床试验阶段。本文对近年来国内外新药研发的现状作了疏理,并对临床治愈或彻底治愈的方案提出建议。Viral hepatitis B is one of the most widespread and harmful infectious diseases in China,and also is a worldwide disease burden seriously threatening human health.According to data released by the Polaris Observatory Collaborators,in China there were 79.74 million people infected with hepatitis B virus in 2022.In the past two years,the research and development of new drugs has advanced rapidly.A variety of new anti-hepatitis B treatment small molecule drugs and immunomodulatory inhibitors are entering the clinical trial stage.This article reviews the progress on the research and development of major new antiviral drugs for chronic hepatitis B in recent years,and proposes strategies of clinical cure or complete cure for chronic hepatitis B.

关 键 词：肝炎 乙型 慢性 抗病毒药物 小分子药物 免疫调控抑制剂 研究现状 

分 类 号：R512.62[医药卫生—内科学]